A Novel Topical Agent for the Management of Hyperpigmentation, Including Melasma and Age Spots

Melasma and age spots are among the most persistent and difficult-to-treat forms of hyperpigmentation. While traditional therapies offer some clinical efficacy, they often carry risks of irritation and rebound pigmentation. This study aims to evaluate the therapeutic potential and user tolerability of nanodiamond-zinc oxide (ND-ZnO)-containing skin preparations in improving hyperpigmentation conditions through 11 individual case series and 32 user-reported outcomes.

We analyzed 11 real-world case studies involving daily usage of ND-ZnO-containing cream and serum over a period of 4 to 12 weeks. Participants varied in age, ethnicity, and Fitzpatrick skin type (FST). Cases were selected based on adherence, diversity of presentation, and completeness of photographic and evaluative documentation.

All 11 case participants demonstrated visible improvements in hyperpigmentation, with varying degrees of reduction in melasma and age spots. Among 32 questionnaire respondents, 90.63% reported a visible reduction in hyperpigmentation, 96.9% noted brighter and more even skin tone, and 93.75% observed improved radiance. All participants tolerated the treatment well, with 100% non-irritation confirmed by two separate Human Repeat Insult Patch Test (HRIPT) studies.

ND-ZnO-containing skin preparations offer a well-tolerated and effective alternative to conventional treatments for melasma and age spots. Their multi-action approach, which combines UV protection, reactive oxygen species (ROS) scavenging, and enhanced delivery of actives, supports both prevention and repair of pigmentation. These findings suggest ND-ZnO formulations may serve as a safer and more compliant option for long-term hyperpigmentation management.  .